Research Group Endres

Association Between Dispatch of Mobile Stroke Units and Functional Outcomes Among Patients With Acute Ischemic Stroke in Berlin.
Ebinger M, Siegerink B, Kunz A, Wendt M, Weber JE, Schwabauer E, Geisler F, Freitag E, Lange J, Behrens J, Erdur H, Ganeshan R, Liman T, Scheitz JF, Schlemm L, Harmel P, Zieschang K, Lorenz-Meyer I, Napierkowski I, Waldschmidt C, Nolte CH, Grittner U, Wiener E, Bohner G, Nabavi DG, Schmehl I, Ekkernkamp A, Jungehulsing GJ, Mackert BM, Hartmann A, Rohmann JL, Endres M, Audebert HJ;
JAMA. 2021 Feb 2;325(5):454-466.

Endothelial and Leukocyte-Derived Microvesicles and Cardiovascular Risk After Stroke: PROSCIS-B.
Huo S, Kränkel N, Nave AH, Sperber PS, Rohmann JL, Piper SK, Heuschmann PU, Landmesser U, Endres M, Siegerink B, Liman TG.
Neurology. 2021 Feb 9;96(6):e937-e946

Effects of Inhibition or Deletion of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) on Intracerebral Hemorrhage Volumes in Mice.
Schlunk F, Fischer P, Princen HMG, Rex A, Prinz V, Foddis M, Lütjohann D, Laufs U, Endres M.
Stroke. 2020 Nov;51(11):e297-e298. doi: 10.1161/STROKEAHA.120.030087. Epub 2020 Oct 19.
PMID: 33070710.

Physical Fitness Training in Patients with Subacute Stroke (PHYS-STROKE): multicentre, randomised controlled, endpoint blinded trial.
Nave AH, Rackoll T, Grittner U, Bläsing H, Gorsler A, Nabavi DGDG, Audebert HJHJ, Klostermann F, Müller-Werdan U, Steinhagen-Thiessen E, Meisel A, Endres M, Hesse S, Ebinger M, Flöel A.
BMJ. 2019;366.

TRELAS Study Group: Coronary Angiographic Findings in Acute Ischemic Stroke Patients With Elevated Cardiac Troponin: The Troponin Elevation in Acute Ischemic Stroke (TRELAS) Study.
Mochmann, H.C., Scheitz, J.F., Petzold, G.C., Haeusler, K.G., Audebert, H.J., Laufs, U., Schneider, C., Landmesser, U., Werner, N., Endres, M., Witzenbichler, B., Nolte, C.H., TRELAS Study Group.
Circulation. 2016;133(13):1264-71.

Functional outcomes of pre-hospital thrombolysis in a mobile stroke treatment unit compared with conventional care: an observational registry study.
Kunz, A., Ebinger, M., Geisler, F., Rozanski, M., Waldschmidt, C., Weber, J.E., Wendt, M., Winter, B., Zieschang, K., Fiebach, J.B., Villringer, K., Erdur, H., Scheitz, J.F., Tütüncü, S., Bollweg, K., Grittner, U., Kaczmarek, S., Endres, M., Nolte, C.H., Audebert, H.J.
Lancet Neurol. 2016;15(10):1035-43.

Impact of standardized MONitoring for Detection of Atrial Fibrillation in Ischemic Stroke (MonDAFIS): Rationale and design of a prospective randomized multicenter study.
Haeusler, K.G., Kirchhof, P., Heuschmann, P.U., Laufs, U., Busse, O., Kunze, C., Thomalla, G., Nabavi, D.G., Röther, J., Veltkamp, R., Endres, M.
Am Heart J. 2016;172:19-25.

• Post stroke depression
• Endothelial function in cerebrovascular diseases
• Inflammation and stroke
• Cognitive deficits after critical illness
• Mechanisms of Ischemic Tolerance
• Neurotoxicology
• Regeneration after stroke
• Risk factors
• Telemedicine
• Vascular mechanisms of stroke protection
• Cerebral haemorrhage
• Global neurology

Find more details about the research fields on the website of the Department of Experimental Neurology.

AF Registry – Berlin Cohort Study on Oral Anticoagulation in Patients with Atrial Fibrillation and Acute Ischemic Stroke

The study is an -nvestigator-initiated, prospective, multi-centre cohort study using the established collaborative group of the Berlin Stroke Register (BSR) to gather data on eligible stroke patients and to investigate in the city of Berlin about the secondary prevention for stroke and the adherence regarding the prescriptions in patients with known atrial fibrillation and ischemic stroke.

More information/project description
 

CORONA-IS

The primary objective of the "CORONA-IS" study ("Cardiomyocyte Injury Following Acute Ischemic Stroke") is to explore the developmental mechanisms of stroke-associated, acute myocardial damage in an interdisciplinary approach.

More information/project description
 

MonDAFIS – Impact of standardized MONitoring for Detection of Atrial Fibrillation in Ischemic Stroke

Investigator-initiated, prospective, randomized, open-label, multi-center trial with two parallel groups. Randomization of patients happened 1:1 into one group that received standard care and one group that received standard care plus additional Holter ECG monitoring.

More information/project description
 

Neuropsychiatric disorders and stroke

We seek to make further inroads into understanding the complex interaction between depression and brain ischemia at a mechanistic level.

More information/project description
 

PRAISE

The primary goal of the "PRAISE" ("Prediction of Acute Coronary Syndrome in Acute Ischemic Stroke") study is to develop a diagnostic algorithm that allows the prediction of acute coronary syndrome in stroke patients.

More information/project description
 

PROSCIS-B – The CSB Prospective Stroke Cohort

This experiment investigates the process of stroke and the risk of sequelae.

More information/project description
 

PHYS-STROKE and BAPTISe

In "PHYS-STROKE" ("Physical Fitness Training in Patients with Subacute Stroke") we assessed the efficacy and safety of an aerobic fitness training early after stroke on activities of daily living. In "BAPTISe" ("Biomarkers and Perfusion – Training-Induced Changes After Stroke") we aim to find blood- and imaging-based, prognostic markers of functional recovery after stroke.

AXIOMATIC-SSP

A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel (AXIOMATIC-SSP)
The AXIOMATIC SSP study is a global, phase 2, randomized, double-blind, placebo-controlled, dose-ranging Study of BMS-987177, an oral factor XIa inhibitor, for the prevention of new ischemic stroke or new silent brain infraction in patients receiving aspirin and clopidogrel following acute non-hemorrhagic stroke or transient ischemia attack (TIA).
The purpose of this clinical study is to determine whether the addition of an oral Factor XIa Inhibitor to aspirin and clopidogrel is more effective than standard therapy in secondary stroke prevention.

More information/project description

ENRICH-AF

Edoxaban fo Intracranial Hemorrhage Survivors with Atrial Fibrillation
The objective of the ENRICH-AF study is to evaluate whether edoxaban is superior to standard medical therapy in reducing the risk of stroke in high-risk atrial fibrillation patients with previous intracranial hemorrhage.
Patients who fulfill all inclusion and none of the exclusion criteria after giving informed consent will be randomly allocated 1:1 to either edoxaban 60 mg (dose adjusted to 30 mg) daily or standard medical therapy (either no antithrombotic therapy or antiplatelet monotherapy). Randomization will be stratified by center and by qualifying intracranial hemorrhage subtype (subdural vs. non-subdural). The study is event-driven and thus, all patients will be treated (or followed-up in case of premature discontinuation of study medication) until 123 confirmed primary efficacy outcomes have occurred.
The primary efficacy objective is to evaluate whether edoxaban (60/30 mg daily) compared to standard of care (either no antithrombotic therapy or antiplatelet monotherapy) reduces the risk of stroke (composite of ischemic, hemorrhagic and unspecified stroke) in high-risk atrial fibrillation patients with previous intracranial hemorrhage.
The primary safety objective is to document the incidence of clinically relevant major bleeding.

More information/project description

Scientific staff

• PD Dr. med. Wolfgang Böhmerle
• Dr. med. Julius Emmrich
• Prof. Dr. med. Karen Gertz
• PD Dr. med. Petra Hühnchen
• Dr. med. Samuel Knauss
• Dr. rer. nat. Nielsen Lagumersindez Denis
• PD Dr. med. Thomas Liman
• PD Dr. med. Alexander Nave
• Christian Schinke
• Johanna Schöner
• Ria Uhlemann, Dipl.-Biol. PhD

Associated members

• Prof. Dr. med. Dr. phil. Martin Ebinger
• Dr. rer. nat. Friederike Klempin
• Prof. Dr. med. Golo Kronenberg
• Dr. med. Vincent Prinz
• Prof Dr. med. Jan Scheitz

Students

• Carolin Albrecht
• Adam David Dordevic
• Paul Fischer
• Lorena Ginesta Roque
• Marie-Louise Herzog, MSc
• Kerstin Hohgräwe
• Ruben Jödicke
• Bernadette Kirzinger
• Johannes Kern
• Majed Kikhia, MSc
• Smilla Maierhof
• Sarah Müller
• Viktoria Schaeff
• Maria Stillfried
• Wen Pan, MSc
• Julia Riedmann

Technical staff

• Stefanie Balz
• Bettina Herrmann
• Melanie Kroh
• Petra Loge

International

• C. Ayata, Boston, USA
• B.E. Ehrlich, New Haven, USA
• R. Frostig, Irvine, USA
• S. Hazen, Cleveland, USA
• M.A. Moskowitz, Boston, USA
• M. Elkind, New York, USA

National

• T. Bärnighausen, Heidelberg
• E. Binder, Munich
• M. Dichgans, Munich
• T. Hagenacker, Essen
• L. Heinzerling, Munich
• K.G. Häußler, Würzburg
• P.U. Heuschmann, Würzburg
• H. Lehmann, Cologne
• G. Kempermann, Dresden
• U. Laufs, Leipzig
• M.V. Schmidt, Munich

Berlin area

• M. Bader, MDC
• H. Gerhardt, MDC
• C. Heim, Charité – Universitätsmedizin Berlin
• F. Heppner, Charité – Universitätsmedizin Berlin
• H. Kettenmann, MDC
• U. Kintscher, Charité – Universitätsmedizin Berlin
• T. Kurth, Charité – Universitätsmedizin Berlin
• U. Landmesser, Charité – Universitätsmedizin Berlin
• D. Schmitz, Charité – Universitätsmedizin Berlin
• J. Schulz-Menger, Charité – Universitätsmedizin Berlin
• W. Stenzel, Charité – Universitätsmedizin Berlin
• M. Taupitz, Charité – Universitätsmedizin Berlin
• P. Vajkoczy, Charité – Universitätsmedizin Berlin